Abacus Life Reports Preliminary Third Quarter Financial Results
- Anticipated Revenue: $26.0 to $28.0 Million, Reflecting 23-33% Year-over-Year Growth
- Projected GAAP Net Loss: Between ($6.0) and ($6.75) Million Due to Non-Cash Warrant Liability Increase Estimation
- Adjusted EBITDA Expected: Between $14.0 and $16.0 Million, Showing Growth of 30-48% Year-over-Year
- Earnings Release and Conference Call Scheduled for November 7, 2024
Introduction to Abacus Life's Performance
In a recent announcement, Abacus Life, Inc. (NASDAQ: ABL) revealed its preliminary third-quarter results for 2024, showcasing a promising financial trajectory. The company, recognized for its expertise in lifespan-based financial products, anticipates significant growth statistics across several key performance metrics.
Financial Highlights for Third Quarter 2024
The preliminary financial analysis by Abacus indicates a robust performance in the third quarter, outlining expectations for:
Total Revenue Expectations
The company foresees total revenue to fall within the range of $26.0 and $28.0 million, marking a commendable increase of 23% to 33% compared to the previous year. This growth exemplifies Abacus's resilience and dedication to its core revenue streams.
GAAP Net Income Details
Projected net income for the third quarter is estimated between a loss of $6.0 million and $6.75 million. This anticipated loss is primarily attributed to a non-cash adjustment for the increase in the warrant liability, expected to amount between $8.0 million and $9.0 million.
Adjusted EBITDA Projections
For Adjusted EBITDA, Abacus expects to report figures ranging between $14.0 million and $16.0 million, translating into a 30-48% growth year-over-year. This measure illustrates Abacus's operational efficiency and its commitment to delivering value.
Strategic Acquisitions and Management Enhancements
In addition to financial forecasts, Abacus Life announced strategic acquisitions aimed at enhancing its service offerings. Notably, the company acquired Carlisle Management Company SCA and FCF Advisors, expanding its market reach and operational capabilities.
Furthermore, Abacus is strengthening its leadership team with the appointment of Corey McLaren as Managing Director of Capital Markets and Robert F. Phillips as Senior Vice President of Investor Relations and Corporate Affairs. These additions are expected to drive innovative strategies and foster investor relations.
Innovative Health Tools and Future Initiatives
Building on its innovative spirit, Abacus has partnered with Lorisco to introduce PREADISAN™, a cutting-edge health prediction and actuarial technology tool. This game-changing tool is set to offer personalized longevity forecasting, enhancing the financial solutions provided to clients.
Upcoming Earnings Release and Conference Call Information
Abacus Life is set to disclose its finalized financial results for the third quarter post-market closure on November 7, 2024. Following the release, management will host a conference call at 5:00 PM Eastern Time, providing insights into the financial outcomes and strategic outlook moving forward. Interested investors can access a live webcast through the company's investor relations site.
About Abacus Life
Abacus Life, Inc. stands as a prominent player in the global alternative asset management sphere, particularly in lifespan-based financial offerings. With nearly $3 billion in assets under management, the company is distinguished as the only public alternative asset manager focused on this niche, trading on the Nasdaq exchange.
The firm has recently ventured into new sectors, launching ABL Wealth for longevity-oriented wealth management and ABL Tech, which focuses on pioneering technology services. These initiatives signify Abacus's commitment to revolutionizing the life insurance landscape.
Frequently Asked Questions
What are the expected revenues for Q3 2024?
Abacus Life anticipates revenues between $26.0 and $28.0 million, reflecting a growth of 23-33% year-over-year.
What is the projected Adjusted EBITDA?
Projected Adjusted EBITDA for the quarter is between $14.0 and $16.0 million, indicating a healthy growth rate of 30-48% compared to last year.
When will the earnings release take place?
The earnings release and conference call for Q3 results are scheduled for November 7, 2024.
What recent acquisitions has Abacus made?
Abacus has recently acquired Carlisle Management Company SCA and FCF Advisors, enhancing its capabilities in the alternative asset management sector.
How is Abacus utilizing new technology in its services?
Abacus has launched PREADISAN™, a revolutionary tool for health prediction and actuarial analysis, aimed at offering personalized financial solutions based on longevity forecasts.
